Programmed Cell Death and Neurodegenerative Diseases

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Nervous System".

Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 2132

Special Issue Editor

Departament de Biología Cellular, Fisiología i Immunología, Facultat de Biología, Universitat de Barcelona, Barcelona, Spain
Interests: neurodegeneration; Inflammation; brain organoids; ESCs; iPSC
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Many neurodegenerative diseases are characterized by the progressive deterioration of neuronal function caused by the degeneration of synapses, axons and ultimately the death of nerve cells. An increased understanding of the molecular pathways of programmed cell death (PCD) underlying altered cellular homeostasis and neurodegeneration is critical to the development of effective treatments for disease.

In recent decades, studies have elucidated several key cell death signaling pathways as well as their possible consequences. However, in neurodegenerative diseases, the immune system also plays a critical role. Therefore, future cell death studies need to analyze cell death machinery and explore the physiological response of the immune system to each cell death mechanism in order to develop new therapeutic approaches.

This Special Issue will present cutting-edge views on the mechanisms that determine those effects and consequences of programmed cell death in the surrounding microenvironment of many neurodegenerative diseases. Additionally, this Special Issue will cover promising, recent and novel research trends exploring the relationship of cell death mechanisms and surrounding cell responses. Original research, reviews and mini-reviews are welcome.

The topics will include, but are not limited to:

  • Discoveries in novel cell death modes.
  • Mechanisms that determine the physiological impact of dead cells.
  • The role of cell death in physiological and pathological processes, such as Alzheimer’s disease, Parkinson’s disease, ALS, HD, etc.
  • Mechanisms that determine the physiological impact of dead cells.
  • Therapeutic implications of cell death regulation.
  • The non-killing function of cell death machinery.
  • New approaches to prevent cell death in neurodegenerative diseases.

Dr. Ana Sevilla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegeneration
  • cell death
  • neuroinflammation
  • apoptotic pathways
  • neuronal loss
  • Parkinson’s disease
  • Alzheimer’s disease
  • Huntington disease
  • ALS

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 1199 KiB  
Review
Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF): An Emerging Therapeutic Target for Neurodegenerative Disorders
by Bhadrapriya Sivakumar and Anand Krishnan
Cells 2023, 12(7), 1032; https://doi.org/10.3390/cells12071032 - 28 Mar 2023
Cited by 1 | Viewed by 1659
Abstract
Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a member of the new family of neurotrophic factors (NTFs) with a unique structure and functions compared to other conventionally known NTFs. MANF is broadly expressed in developing and mature tissues, including the central nervous system and [...] Read more.
Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a member of the new family of neurotrophic factors (NTFs) with a unique structure and functions compared to other conventionally known NTFs. MANF is broadly expressed in developing and mature tissues, including the central nervous system and peripheral nervous system tissues. Growing research demonstrated that MANF protects neurons from endoplasmic reticulum (ER) stress-associated complications by restoring ER homeostasis and regulating unfolded protein response. This review discusses MANF signaling in neurodegenerative conditions with specific emphasis given to its overall effect and mechanisms of action in experimental models of Parkinson’s disease, Alzheimer’s disease, and stroke. Additional perspectives on its potential unexplored roles in other neurodegenerative conditions are also given. Full article
(This article belongs to the Special Issue Programmed Cell Death and Neurodegenerative Diseases)
Show Figures

Figure 1

Back to TopTop